Article de Périodique
Efficacy of cannabidiol alone or in combination with Delta-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence (2025)
Auteur(s) :
REDONNET, B. ;
EREN, F. ;
AVENIN, G. ;
MELCHIOR, M. ;
MARY-KRAUSE, M.
Année
2025
Page(s) :
813-834
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
77
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs ; Plusieurs produits / Several products
Thésaurus mots-clés
CANNABIDIOL
;
EFFICACITE
;
ADDICTION
;
USAGE THERAPEUTIQUE
;
TETRAHYDROCANNABINOL
;
TRAITEMENT
Résumé :
BACKGROUND AND AIMS: Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as a potential therapeutic target due to its pharmacological properties and mode of action in the endocannabinoid system. Recent systematic reviews (SR) on CBD and SUDs have shown inconsistent results. The objective of this umbrella review was to determine whether CBD alone or in combination with Δ-9-tetrahydrocannabinol (THC) is effective for managing and treating SUDs.
METHODS: Following a registered protocol, we searched PubMed, Web of Science and Epistemonikos databases for SRs, with or without a meta-analysis, of randomized controlled trials focusing on interventions dispensing CBD, alone or in combination with THC, to treat SUDs, published from 1 January 2000 to 15 October 2024. Screening, data extraction and quality assessment with the AMSTAR 2 tool were performed by two researchers in parallel and duplicated.
RESULTS: 22 SRs were included, 5 of which performed a meta-analysis. We found mixed evidence regarding the efficacy of CBD to manage and treat SUDs. Findings were interpreted in light of the quality of the SRs. Nabiximols, which contains CBD and THC, demonstrated positive effects on cannabis withdrawal and craving symptoms. Evidence supporting the efficacy of CBD is limited and inconclusive for abstinence, reduction or cessation of use of cannabis, tobacco, alcohol, opiates and other psychoactive substances.
CONCLUSION: Cannabidiol (CBD) monotherapy does not appear to be efficacious for treatment of substance use disorders. CBD primarily exhibits effects on cannabis withdrawal and craving when combined with Δ-9-tetrahydrocannabinol (THC). Existing data on the efficacy of CBD alone with regard to other outcomes related to substance use disorders are limited. [Author's abstract]
METHODS: Following a registered protocol, we searched PubMed, Web of Science and Epistemonikos databases for SRs, with or without a meta-analysis, of randomized controlled trials focusing on interventions dispensing CBD, alone or in combination with THC, to treat SUDs, published from 1 January 2000 to 15 October 2024. Screening, data extraction and quality assessment with the AMSTAR 2 tool were performed by two researchers in parallel and duplicated.
RESULTS: 22 SRs were included, 5 of which performed a meta-analysis. We found mixed evidence regarding the efficacy of CBD to manage and treat SUDs. Findings were interpreted in light of the quality of the SRs. Nabiximols, which contains CBD and THC, demonstrated positive effects on cannabis withdrawal and craving symptoms. Evidence supporting the efficacy of CBD is limited and inconclusive for abstinence, reduction or cessation of use of cannabis, tobacco, alcohol, opiates and other psychoactive substances.
CONCLUSION: Cannabidiol (CBD) monotherapy does not appear to be efficacious for treatment of substance use disorders. CBD primarily exhibits effects on cannabis withdrawal and craving when combined with Δ-9-tetrahydrocannabinol (THC). Existing data on the efficacy of CBD alone with regard to other outcomes related to substance use disorders are limited. [Author's abstract]
Affiliation :
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique [IPLESP], Epidémiologie Sociale, Santé Mentale et Addictions [ESSMA], Paris, France.
Sorbonne Université, Faculté de Médecine Saint-Antoine, Département de Médecine Générale, Paris, France.
Sorbonne Université, Faculté de Médecine Saint-Antoine, Département de Médecine Générale, Paris, France.
Cote :
Abonnement numérique
Historique